High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B

Gut

Volumn 54, Issue 1, 2005, Pages 152-161

  Lin, C L ^c   Tsai, S L ^a,b   Lee, T H ^d   Chien, R N ^d   Liao, S K ^d   Liaw, Y F ^d  

^a CHI MEI FOUNDATION HOSPITAL   (Taiwan)

^b Queen Mary Hospital ^*  (Taiwan)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; INTERLEUKIN 2; LAMIVUDINE; PROTEIN ANTIBODY; TETRAMER; TYROSYLMETHIONYLASPARTYLASPARTATE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CELL MUTANT; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; T LYMPHOCYTE RECEPTOR GENE; VIRUS MUTANT;

ADULT; AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 10844242136     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.032920     Document Type: Article

References (52)

1. Lai CL, Chien RH, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
2. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999;58:101-41.
3. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B. N Engl J Med 1999;341:1256-63.
4. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
5. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
6. Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-99.
7. Dienstag JL, Perillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
8. Mckenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis. N Engl J Med 1995;333:1099-105.
9. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
10. Chang TT, Lai CL, Liaw YF, Guan R, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years. Antiviral Ther 2000;5(suppl 1):44.
11. Bartholomew M, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplatation. Lancet 1997;349:3-4.
12. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7.
13. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
14. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
15. Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403-5.
16. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplation. Gastroenterology 2002;122:264-73.
17. Honkoop P, Niesters HGM, Man RA, et al. Lamivudine resistance in immunocompetent chronic hepatitis B; Incidence and patterns. J Hepatol 1997;26:1393-5.
18. Wainberg MA, Drosopoulos WC, Salomon H, et al. Enhanced fidelity of 3TC selected mutant HIV-1 reverse transcriptase. Science 1996;271:1282-5.
19. Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998;339:114-15.
20. Chien RN, Yeh CT, Tsai SL, et al. The determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
21. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-58.
22. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-75.
23. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
24. Lee TH, Chuang YL, Tsai SL, et al. Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte response via peptide-MHC terrameric complexes assay. Lett Pept Sci 2002;8:179-85.
25. Maini MK, Boni C, Ogg GS, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 1999;117:1386-96.
26. Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8+ cell in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80.
27. Reignat S, Webster GJM, Brown D, et al. Escaping high viral load exhaustion: CDS cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002;195:1089-101.
28. Tsai SL, Sheen IS, Chien RN, et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci 2003;10:120-35.
29. He X-S, Rehermann B, López-Labrador FX, et al. Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999;96:5692-7.
30. Lauer GM, Nguyen TN, Day CL, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002;76:2817-26.
31. +-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002;76:6104-13.
32. Yeh CT, Liaw YF, Ou JH. The arginine-rich domain of hepatitis B virus precore and core protein contains a signal for nuclear transport. J Virol 1990;64:6141-7.
33. Tsai SL, Chen MH, Yeh CT, et al. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. J Clin Invest 1996;97:577-84.
34. Tsai SL, Chen PJ, Liao TH, et al. Characterization of T cell clones specific to a determinant of hepatitis B virus core and e antigens in chronic type B hepatitis: implication for T cell mechanism of HBV immunopathogenesis. J Biomed Sci 1994;1:105-18.
35. Tsai SL, Lai MY, Chen DS. Analysis of rearranged T cell receptor (TCR) Vβ transcripts in livers of primary biliary cirrhosis: preferential Vβ usage suggests antigen-driven selection. Clin Exp Immunol 1996;103:99-104.
36. Toyonaga B, Mak TW. Genes of the T- cell antigen receptor in normal and malignant T cells. Annu Rev Immunol 1987;5:585-620.
37. Arden B, Clark SP, Kabelitz D, et al. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455-500.
38. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-71.
39. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55.
40. Bertoni R, Sidney J, Fowler P, et al. Human histocompatibility leucocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte respondes in patients with acute hepatitis. J Clin Invest 1997;100:503-13.
41. Sarobe P, Pendleton CD, Akatsuka T, et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding position. J Clin Invest 1998;102:1239-48.
42. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996;24:996-1002.
43. Bertoletti A, Sette A, Chisari FV, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994;369:407-10.
44. Tsai SL, Chen YM, Chen MH, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998;115:954-66.
45. Paik YH, Chung HY, Ryu WS, et al. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol 2001;35:92-8.
46. Nafa S, Ahmed S, Chayama D, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-16.
47. Kobayashi S, Ide T, Sata H. Detection of YMDD mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-6.
48. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic nepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-7.
49. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
50. Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-12.
51. Kaa JH. Hepatitis B viral genotypes: Clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-50.
52. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, et al. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat 2003;10:256-65.